Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00112619 | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors | terminated | Phase 1 | 19 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00538876 | Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | completed | Phase 1 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00004084 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | 21 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00004107 | Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 18 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00926731 | Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 2 | Jun 16, 2011 | clinicaltrials |
| NCT00002681 | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 / Phase 2 | 25 | Roger Williams Medical CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML(ADcomparison) | completed | Phase 3 | 398 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00112775 | BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 7, 2011 | clinicaltrials |
| NCT00261677 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | completed | Phase 3 | 224 | Ortho Biotech Products, L.P.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00521664 | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | completed | Phase 3 | 400 | Technische Universität DresdenOTHER | 1 | May 19, 2011 | clinicaltrials |
| NCT00844441 | Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | N/A | 96 | Fred Hutchinson Cancer CenterOTHER | 2 | May 19, 2011 | clinicaltrials |
| NCT00270049 | Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | completed | Phase 2 | 195 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00042822 | FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00661999 | Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer | completed | Phase 3 | 502 | Mayo ClinicOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00806767 | Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer | completed | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00540956 | Natural Killer Cells in Older Patients With Acute Myeloid Leukemia | completed | N/A | 40 | Institut Paoli-CalmettesOTHER | 1 | May 16, 2011 | clinicaltrials |
| NCT00840684 | Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 135 | Institut Paoli-CalmettesOTHER | 1 | May 13, 2011 | clinicaltrials |
| NCT00963521 | Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission | completed | Phase 1 | 10 | Institut Paoli-CalmettesOTHER | 1 | May 13, 2011 | clinicaltrials |
| NCT00002504 | Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00049413 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00559624 | Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients | completed | Phase 1 / Phase 2 | 40 | Advancell - Advanced In Vitro Cell Technologies, S.A.INDUSTRY | 3 | May 10, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT00978731 | Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 28, 2011 | clinicaltrials |
| NCT01141673 | Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT01339988 | Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) | unknown | Phase 4 | 10 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 21, 2011 | clinicaltrials |
| NCT00101647 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | completed | Phase 2 | 197 | Bristol-Myers SquibbINDUSTRY | 23 | Apr 15, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT00103701 | BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia | completed | Phase 1 | — | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00337454 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | completed | Phase 1 / Phase 2 | 48 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00226512 | To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning | withdrawn | Phase 3 | 203 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
| NCT00186966 | Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 3 | 394 | Dutch Childhood Oncology GroupOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT01329471 | Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) | unknown | — | 75 | Hillel Yaffe Medical CenterOTHER_GOV | 1 | Apr 6, 2011 | clinicaltrials |
| NCT00400673 | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia | completed | Phase 2 | 581 | Northern Italy Leukemia GroupOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT00187005 | Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | terminated | Phase 3 | 53 | St. Jude Children's Research HospitalOTHER | 1 | Mar 30, 2011 | clinicaltrials |
| NCT01114087 | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility(GLIFERTI) | completed | N/A | 2 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00003331 | Combination Chemotherapy in Treating Patients With Advanced Cancer | completed | Phase 1 | 30 | NYU Langone HealthOTHER | 1 | Mar 28, 2011 | clinicaltrials |
| NCT00004105 | Combination Chemotherapy in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 28, 2011 | clinicaltrials |
| NCT01315925 | Pre-hospital Risk Factors for Invasive Fungal Infection(SEIFEM 2010) | unknown | — | 1,000 | Catholic University of the Sacred HeartOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00136422 | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136448 | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136461 | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00251368 | Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia | completed | Phase 1 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00053131 | Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00053144 | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | completed | Phase 1 | — | Roswell Park Cancer InstituteOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00003294 | Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Mar 7, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 30, 2011source: clinicaltrials